Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

670 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ａretrospective study was conducted to compare the efficacy, safety, and cost-effectiveness of traditional proton pump inhibitors (PPI ) and Potassium-competitive acid blockers ( P-CAB )for clarithromycin-based bismuth-containing quadruple therapy in the management of Helicobacter pylori eradication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

NCT07285096

Helicobacter Pylori Infection

RECRUITING

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

NCT07167511

Helicobacter Pylori Infection

COMPLETED

Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy

NCT05237115

Gastritis Peptic Ulcer Dyspepsia

COMPLETED PHASE4

Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

NCT02776371

Helicobacter Pylori Eradication Rate

COMPLETED PHASE4

Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

NCT03571230

Helicobacter Pylori Infection Antimicrobial Susceptibility Testing

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study retrospectively enrolled participants with H. pylori infection who received bismuth quadruple regimen containing clarithromycin. The basic information, treatment results, adverse reactions and compliance of the patients were collected. According to the type of acid inhibitors, participants were divided into traditional PPI group and P-CAB group. Traditional PPI group which were divided into lansoprazole group and esomeprazole group. The eradication rate, safety, compliance of H. pylori in different treatment regimens was evaluated. Multivariate analysis was performed to identify predictors of eradication failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori; Eradication Rate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PPI group

PPI regimen

Intervention Type OTHER

All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.

P-CAB group

P-CAB regimen

Intervention Type OTHER

All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PPI regimen

All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.

Intervention Type OTHER

P-CAB regimen

All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants aged 18-75 years with persistent H. pylori infection.
* Participants received clarithromycin-based bismuth-containing quadruple therapy.

Exclusion Criteria

* Patients received rescue therapy
* Patients treated with PPI, P-CAB,bismuth and antibiotics in the previous 4 weeks
* Patients with gastorectomy
* Currently pregnant or lactating or other conditions unable to receive therapy
* Severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk
* Severe neurologic or psychiatric disorders
* Information incomplete

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No